Marrone Bio Innovations Inc Forecasted to Post FY2017 Earnings of ($1.10) Per Share (MBII)

Marrone Bio Innovations Inc (NASDAQ:MBII) – Equities researchers at Jefferies Group issued their FY2017 earnings per share estimates for Marrone Bio Innovations in a report released on Thursday. Jefferies Group analyst L. Alexander forecasts that the basic materials company will post earnings per share of ($1.10) for the year. Jefferies Group also issued estimates for Marrone Bio Innovations’ Q4 2017 earnings at ($0.26) EPS, FY2018 earnings at ($0.13) EPS, FY2019 earnings at ($0.10) EPS, FY2020 earnings at ($0.07) EPS and FY2021 earnings at ($0.03) EPS.

Marrone Bio Innovations (NASDAQ:MBII) last posted its quarterly earnings data on Monday, November 13th. The basic materials company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). The business had revenue of $4.22 million for the quarter, compared to the consensus estimate of $5.32 million.

A number of other equities analysts have also recently weighed in on MBII. HC Wainwright set a $4.00 price objective on shares of Marrone Bio Innovations and gave the company a “buy” rating in a research report on Thursday, December 21st. ValuEngine raised shares of Marrone Bio Innovations from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $2.50.

Marrone Bio Innovations (NASDAQ MBII) opened at $1.24 on Monday. The company has a debt-to-equity ratio of -1.14, a current ratio of 0.69 and a quick ratio of 0.36. The firm has a market cap of $38.88, a PE ratio of -1.08 and a beta of 0.26. Marrone Bio Innovations has a 12-month low of $0.85 and a 12-month high of $2.30.

An institutional investor recently raised its position in Marrone Bio Innovations stock. Ardsley Advisory Partners lifted its stake in shares of Marrone Bio Innovations Inc (NASDAQ:MBII) by 375.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,681,580 shares of the basic materials company’s stock after purchasing an additional 2,907,142 shares during the period. Ardsley Advisory Partners owned about 11.74% of Marrone Bio Innovations worth $4,528,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 37.59% of the company’s stock.

In other news, insider Ardsley Advisory Partners acquired 6,666,667 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was bought at an average cost of $0.75 per share, with a total value of $5,000,000.25. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 2.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at

Marrone Bio Innovations Company Profile

Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.

Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with's FREE daily email newsletter.

Leave a Reply